# OncoLens

> OncoLens is an Atlanta health-tech company that turns the tumor board - the committee where oncologists, surgeons, radiologists and pathologists jointly decide how to treat a cancer patient - into cloud software. Its platform pulls structured and unstructured data out of EMRs, labs and pathology reports, uses AI to prep cases and flag patients for clinical trials and biomarker testing, and runs inside more than 225 cancer centers covering roughly five million patients.

- **Founded:** 2017
- **Headquarters:** Atlanta, United States
- **Founders:** Anju Mathew (Co-Founder and CEO), Dr. Lijo Simpson (Co-Founder and Chief Medical Officer)
- **Team size:** ~35 employees
- **Products:** Virtual Tumor Board, AI Patient Identification, Clinical Trial Matching, Molecular / Biomarker Analysis, Oncology Registry Automation
- **Notable:** Named to the Inc. 5000 list of fastest-growing private US companies in 2023 (#316) and 2024 (#1296), Grew to 225+ cancer centers and ~5 million patients under care, Facilitated 278,000+ multidisciplinary case discussions

## Products & services

- **Virtual Tumor Board** — Automates tumor-board case intake, data collection, CME tracking and accreditation reporting, pulling patient data from EMRs, labs and pathology into a single case packet and cutting preparation time by over 90%.
- **AI Patient Identification** — Uses natural language processing to read unstructured clinical notes and identify relevant patients - for trials, biomarker testing or board review - with a reported 85-90% accuracy.
- **Clinical Trial Matching** — Automatically aligns patients to open clinical trials using EMR and molecular data, surfacing candidates before a coordinator opens the chart.
- **Molecular / Biomarker Analysis** — Aggregates genomic and biomarker data to support molecular tumor boards and precision-therapy decisions.
- **Oncology Registry Automation** — Extracts and standardizes cancer data for registry reporting and accreditation bodies such as the Commission on Cancer and NAPBC.
- **OncoLens Research Network (ORN)** — Connects life-science and pharma companies with cancer centers for real-world data and research collaboration.

## Achievements

- Named to the Inc. 5000 list of fastest-growing private US companies in 2023 (#316) and 2024 (#1296)
- Grew to 225+ cancer centers and ~5 million patients under care
- Facilitated 278,000+ multidisciplinary case discussions
- Achieved SOC 2 certification (2022)
- Raised ~$27.15M total across Seed, Series A and Series B
- CEO Anju Mathew named a 2025 Georgia Titan 100 honoree

## Latest updates

- **2024-10** — Raised $16M Series B co-led by BIP Capital and Cross Border Impact Ventures to expand its cancer treatment platform and research network.
- **2024-08** — Ranked #1296 on the Inc. 5000 list of fastest-growing private companies in America.
- **2025-01** — CEO Anju Mathew recognized as a Georgia Titan 100 honoree.

## Links

- Website: https://oncolens.com
- LinkedIn: https://www.linkedin.com/company/oncolens
- Twitter/X: https://twitter.com/oncolens
- Facebook: https://www.facebook.com/OncoLens/

---

Profile page: https://yespress.io/oncolens
Published by YesPress — https://yespress.io
Last updated: 2026-08-19